好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2024 Annual Meeting | Industry Therapeutic Update from Novartis: Unlocking the Latest Data: Why Wait? Early Consideration for an Established B-Cell Therapy with Ease of Administration in RMS

Wednesday 04/17/24
11:45 AM - 12:45 PM MDT Add To Calendar
This program will be presented in-person only
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
Stephen W. Yeung, DO, Jason W. Freeman, MD
General Neurology, Multiple Sclerosis
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
No CME available

Program Evaluations

Event Timeline
11:45 AM - 12:45 PM MDT Speaker Industry Therapeutic Update from Novartis: Unlocking the Latest Data: Why Wait? Early Consideration for an Established B-Cell Therapy with Ease of Administration in RMS
Faculty Disclosures
Stephen W. Yeung, DO Dr. Yeung has received personal compensation for serving as an employee of Novartis.
Jason W. Freeman, MD Dr. Freeman has received personal compensation for serving as an employee of Novartis . Dr. Freeman has stock in Novartis .